SYNC

Syncona proposes investment policy change

Syncona Limited is revamping its investment strategy to enhance shareholder value amid challenging biotech market conditions. Explore their proposed policy changes and cash return options...

Syncona’s Beacon reports positive 6-month data from XLRP trial

Syncona Ltd's portfolio company, Beacon Therapeutics, reveals promising Phase II DAWN trial results for laru-zova, targeting X-linked retinitis pigmentosa (XLRP)...

Syncona launches Slingshot to advance early-stage biotech innovations

Syncona Ltd launches Slingshot Therapeutics, investing £12.5 million to advance academic innovations into biotech with a focus on inflammatory diseases...

Syncona portfolio company Beacon Therapeutics raises $170 million in a Series B financing

Syncona Ltd (LON:SYNC) commits $42.5 million to Beacon Therapeutics' $170 million Series B financing to advance treatments for blinding retinal diseases...

Syncona adds two new companies to its portfolio, iOnctura and Yellowstone Biosciences

Syncona Ltd (LON:SYNC) expands its life science portfolio with €30M in iOnctura and £16.5M in Yellowstone Biosciences, enhancing their oncology innovations...

Syncona quarterly update: Net assets and portfolio value increase, key milestones achieved by portfolio companies

Syncona Limited has issued its quarterly update, reporting an increase in net assets and a positive NAV per share return. The company's life science portfolio also saw significant growth. Read more for details. #Syncona #quarterlyupdate #lifescienceinvestment..

Syncona’s portfolio company, Freeline, releases positive data on gene therapy for Gaucher disease

Syncona Ltd notes further safety and enzyme activity data from its portfolio company, Freeline Therapeutics, on its gene therapy candidate for Gaucher disease...
Search

Funds

SYNC

Syncona proposes investment policy change

Syncona Limited is revamping its investment strategy to enhance shareholder value amid challenging biotech market conditions. Explore their proposed policy changes and cash return options...

Syncona’s Beacon reports positive 6-month data from XLRP trial

Syncona Ltd's portfolio company, Beacon Therapeutics, reveals promising Phase II DAWN trial results for laru-zova, targeting X-linked retinitis pigmentosa (XLRP)...

Syncona launches Slingshot to advance early-stage biotech innovations

Syncona Ltd launches Slingshot Therapeutics, investing £12.5 million to advance academic innovations into biotech with a focus on inflammatory diseases...

Syncona portfolio company Beacon Therapeutics raises $170 million in a Series B financing

Syncona Ltd (LON:SYNC) commits $42.5 million to Beacon Therapeutics' $170 million Series B financing to advance treatments for blinding retinal diseases...

Syncona adds two new companies to its portfolio, iOnctura and Yellowstone Biosciences

Syncona Ltd (LON:SYNC) expands its life science portfolio with €30M in iOnctura and £16.5M in Yellowstone Biosciences, enhancing their oncology innovations...

Syncona quarterly update: Net assets and portfolio value increase, key milestones achieved by portfolio companies

Syncona Limited has issued its quarterly update, reporting an increase in net assets and a positive NAV per share return. The company's life science portfolio also saw significant growth. Read more for details. #Syncona #quarterlyupdate #lifescienceinvestment..

Syncona’s portfolio company, Freeline, releases positive data on gene therapy for Gaucher disease

Syncona Ltd notes further safety and enzyme activity data from its portfolio company, Freeline Therapeutics, on its gene therapy candidate for Gaucher disease...
Search

Funds

SYNC

FTSE 100

Funds